These 2 Numbers Could Spell Trouble for AbbVie Stock
AbbVie (NYSE: ABBV) investors might have a reason to start sweating. After a somewhat weak first quarter, the biopharma company's near future looks like it'll be one with a bit less revenue than expected.
That's something that would always be a problem, but in this case, the issue is a bit more pressing than usual. Before its Q1 earnings report released in late April, management's forecasts already called for a drop in sales. Now, its plans to reverse the negative revenue trend look like they'll need to start working sooner than anticipated.
Let's take a look at two numbers which show why that's the case.
Source Fool.com
